Regeneron Pharmaceuticals, Inc.

WBAG:REGN Stock Report

Market Cap: €99.6b

Regeneron Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 5/6

Regeneron Pharmaceuticals has a total shareholder equity of $28.2B and total debt of $2.0B, which brings its debt-to-equity ratio to 7%. Its total assets and total liabilities are $36.1B and $7.9B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -7.3. It has cash and short-term investments of $9.8B.

Key information

7.0%

Debt to equity ratio

US$1.98b

Debt

Interest coverage ratio-7.3x
CashUS$9.81b
EquityUS$28.21b
Total liabilitiesUS$7.88b
Total assetsUS$36.09b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($19.1B) exceed its short term liabilities ($3.5B).

Long Term Liabilities: REGN's short term assets ($19.1B) exceed its long term liabilities ($4.4B).


Debt to Equity History and Analysis

Debt Level: REGN has more cash than its total debt.

Reducing Debt: REGN's debt to equity ratio has increased from 0% to 7% over the past 5 years.

Debt Coverage: REGN's debt is well covered by operating cash flow (205.2%).

Interest Coverage: REGN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies